Vera Therapeutics, Inc. ( NASDAQ : VERA )

Sector: Healthcare | Industry: Biotechnology

Pre-Market	Intra-Day	After-Hours
38.47 ( +4.42 / +12.98% )	33.93 ( -0.12 / -0.35% )	—
15-Sep 09:20	15-Sep 15:21	14-Sep 18:46

Previous Close	34.05	52-Week Low	23.05
Open	36.70	52-Week High	56.05
Day Low	32.73	50-Day Average	35.07
Day High	37.13	200-Day Average	39.59
Volume	9.4 M	Market Cap	2.44 B

VERA Stock News

Latest news for VERA from CatalystPICR and external news sources.

Showing 1 – 4 of 4 news items for VERA from 2026-09-15 to 2026-09-15

15-Sep-2026

12:28

VERA

What's Going on With Vera Therapeutics Stock on Tuesday?

Benzinga

Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.

15-Sep-2026

12:03

VERA

Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results

Barrons

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.

15-Sep-2026

12:01

VERA

Why is Vera Therapeutics stock reversing its premarket gains?

Invezz

Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).

15-Sep-2026

10:33

VERA

Vera Stock Slides Despite Positive Phase 3 Results

Schaeffers Research

Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company's TRUTAKNA drug.

Create your FREE CatalystPICR account to access MORE news and additional data.